2024 ESC Guidelines for the management of chronic coronary syndromes
This guideline cites 38 of the 199 landmark trials in our Cardiology register.
- Issued by
- ESC
- Year
- 2024
- Source
- Vrints C, Andreotti F, et al. Eur Heart J. 2024;45(36):3415–3537.doi 10.1093/eurheartj/ehae177
The 2024 ESC Guidelines on chronic coronary syndromes (CCS) span diagnosis and risk stratification, anti-anginal and event-prevention therapy, and revascularisation. This page surfaces the landmark trials from our register that the guideline cites — grouped by theme — so you can jump from a recommendation to the evidence that underpins it.
Diagnosis & imaging1
- 2018SCOT-HEARTCardiology · Coronary · CT coronary angiographyIn 4,146 patients with stable chest pain, adding CT coronary angiography reduced 5-year coronary death or non-fatal MI compared with standard care alone.HR 0.5995% CI 0.41-0.84Read →
Revascularisation vs. medical therapy13
- 2023ORBITA-2Cardiology · Coronary · RevascularisationIn 301 patients with stable angina on no antianginal medication, PCI improved the angina symptom score compared with a placebo procedure.OR 2.21Read →
- 2022FAME 3Cardiology · Coronary · FFR-guided PCIIn 1,500 patients with 3-vessel coronary disease, FFR-guided PCI did not prove non-inferior for 1-year death, MI, stroke, or repeat revascularisation compared with CABG.HR 1.595% CI 1.1-2.2Read →
- 2022REVIVED-BCIS2Cardiology · Coronary · PCI vs OMTIn 700 patients with ischaemic LV dysfunction (LVEF ≤35%) and viable myocardium, PCI plus optimal medical therapy did not reduce all-cause death or HF hospitalisation compared with optimal medical therapy alone.HR 0.9995% CI 0.78-1.27Read →
- 2020ISCHEMIA CoreCardiology · Coronary · RevascularisationIn 5,179 patients with stable CAD and moderate-to-severe ischaemia, an initial invasive strategy did not reduce CV death, MI, hospitalisation for unstable angina, HF or resuscitated arrest compared with an initial conservative strategy.HR 0.93Read →
- 2018ORBITACardiology · Coronary · RevascularisationIn 200 patients with stable single-vessel angina, PCI did not improve exercise time at 6 weeks compared with a sham procedure.Read →
- 2016EXCELCardiology · Coronary · left main PCIIn 1,905 patients with left main disease of low-to-intermediate complexity, PCI with everolimus-eluting stents was non-inferior for 3-year death, stroke, or MI compared with CABG.15.4% vs 14.7%Read →
- 2016NOBLECardiology · Coronary · left main PCIIn 1,201 patients with unprotected left main coronary disease, PCI with drug-eluting stents increased 5-year death, MI, repeat revascularisation, or stroke compared with CABG.HR 1.4895% CI 1.11-1.96Read →
- 2016STICHCardiology · HF · CABGIn 1,212 patients with ischaemic cardiomyopathy (EF ≤ 35%) and CAD, coronary-artery bypass grafting plus medical therapy reduced 10-year all-cause mortality compared with medical therapy alone.HR 0.8495% CI 0.73-0.97Read →
- 2012FAME 2Cardiology · Coronary · FFR-guided PCIIn 888 patients with stable coronary disease and a functionally significant (FFR ≤0.80) stenosis, FFR-guided PCI plus medical therapy reduced death, MI, or urgent revascularisation compared with medical therapy alone.HR 0.3295% CI 0.19-0.53Read →
- 2012FREEDOM 2012Cardiology · Coronary · PCI vs CABGIn 1,900 patients with diabetes and multivessel coronary disease, PCI with drug-eluting stents increased death, nonfatal MI, or nonfatal stroke compared with CABG.26.6% vs 18.7%Read →
- 2009FAMECardiology · Coronary · RevascularisationIn 1,005 patients with multivessel CAD, FFR-guided PCI reduced MACE at one year versus angiography-guided PCI.13.2% vs 18.3%Read →
- 2009SYNTAX CoreCardiology · Coronary · PCI vs CABGIn 1,800 patients with 3-vessel or left main coronary disease, PCI with paclitaxel-eluting stents increased 12-month death, stroke, MI, or repeat revascularisation compared with CABG.17.8% vs 12.4%Read →
- 2007COURAGECardiology · Coronary · RevascularisationIn 2,287 patients with stable coronary artery disease, PCI added to optimal medical therapy did not reduce death or non-fatal MI compared with optimal medical therapy alone.HR 1.05Read →
Antithrombotic therapy4
- 2019AUGUSTUS CoreCardiology · Thrombosis · AF + PCIIn 4,614 patients with AF and recent ACS or PCI, apixaban without aspirin reduced major or clinically relevant bleeding compared with warfarin-based triple therapy.Read →
- 2017COMPASSCardiology · Thrombosis · Chronic atherosclerosisIn 27,395 patients with stable coronary or peripheral artery disease, low-dose rivaroxaban plus aspirin reduced cardiovascular death, stroke or MI compared with aspirin alone.HR 0.76Read →
- 2013WOESTCardiology · Thrombosis · AF + PCIIn 573 patients on oral anticoagulation undergoing PCI, clopidogrel without aspirin reduced bleeding compared with triple therapy.HR 0.36Read →
- 2009PLATO CoreCardiology · Coronary · AntiplateletsIn 18,624 patients hospitalised with ACS, ticagrelor reduced CV death, MI or stroke compared with clopidogrel, with similar major bleeding.HR 0.84Read →
Lipid-lowering & anti-inflammatory therapy5
- 2023CLEAR OutcomesCardiology · Lipids · Non-statin LDLIn 13,970 statin-intolerant patients, bempedoic acid reduced major adverse cardiovascular events compared with placebo.HR 0.87Read →
- 2018ODYSSEY OUTCOMESCardiology · Lipids · PCSK9 inhibitorIn 18,924 patients with recent acute coronary syndrome on high-intensity statin, alirocumab reduced major adverse cardiovascular events compared with placebo (HR 0.85, 95% CI 0.78-0.93).HR 0.8595% CI 0.78-0.93Read →
- 2017FOURIERCardiology · Lipids · PCSK9iIn 27,564 patients with ASCVD on statins, evolocumab reduced CV death, MI, stroke, hosp UA or revasc compared with placebo.HR 0.8595% CI 0.79-0.92Read →
- 2017CANTOSCardiology · Lipids · Anti-inflammatoryIn 10,061 patients with prior MI and elevated CRP, canakinumab reduced recurrent cardiovascular events compared with placebo.HR 0.8595% CI 0.74-0.98Read →
- 2015IMPROVE-ITCardiology · Lipids · Non-statin LDLIn 18,144 patients post-ACS, ezetimibe added to simvastatin further reduced CV death, MI, UA, revasc or stroke compared with simvastatin alone.HR 0.94Read →
Cardiometabolic therapy3
- 2023SELECT CoreCardiology · Cardiometabolic · GLP-1 RAIn 17,604 patients with obesity and cardiovascular disease but without diabetes, semaglutide reduced major adverse cardiovascular events compared with placebo.HR 0.8Read →
- 2019DECLARE-TIMI 58Cardiology · Cardiometabolic · SGLT2 inhibitorsIn 17,160 patients with type 2 diabetes, dapagliflozin reduced cardiovascular death or heart-failure hospitalisation compared with placebo.HR 0.83Read →
- 2015EMPA-REG OUTCOME CoreCardiology · Cardiometabolic · SGLT2 inhibitorsIn 7,020 patients with type 2 diabetes and cardiovascular disease, empagliflozin reduced cardiovascular death compared with placebo.HR 0.86Read →
Prevention & RAAS blockade1
- 2000HOPECardiology · Coronary · ACE inhibitorIn 9,297 high-risk patients with vascular disease or diabetes and preserved LV function, ramipril reduced MI, stroke, or cardiovascular death compared with placebo.RR 0.7895% CI 0.70-0.86Read →
Heart failure & LV dysfunction7
- 2022DELIVERCardiology · HF · SGLT2 inhibitorsIn 6,263 patients with heart failure and an ejection fraction > 40 %, dapagliflozin reduced worsening heart failure or cardiovascular death compared with placebo.HR 0.82Read →
- 2021EMPEROR-Preserved CoreCardiology · HF · SGLT2 inhibitorsIn 5,988 patients with HFpEF (EF > 40 %), empagliflozin reduced HF hospitalisation or CV death compared with placebo.HR 0.7995% CI 0.69-0.90Read →
- 2020EMPEROR-ReducedCardiology · HF · SGLT2 inhibitorsIn 3,730 patients with HFrEF (EF ≤ 40 %), empagliflozin reduced cardiovascular death or heart-failure hospitalisation compared with placebo.HR 0.75Read →
- 2019DAPA-HF CoreCardiology · HF · SGLT2 inhibitorsIn 4,744 patients with HFrEF (with or without diabetes), dapagliflozin reduced worsening HF or CV death versus placebo.HR 0.74Read →
- 2014PARADIGM-HF CoreCardiology · HF · ARNIIn 8,442 patients with HFrEF (EF ≤ 0.40), sacubitril/valsartan reduced CV death or hospitalisation for HF compared with enalapril.HR 0.8Read →
- 2003CHARMCardiology · HF · ARBIn 7,601 patients with symptomatic chronic heart failure, candesartan reduced cardiovascular death and heart-failure hospitalisation compared with placebo.HR 0.9195% CI 0.83-1.00Read →
- 1991SOLVDCardiology · HF · ACE inhibitorIn 2,569 patients with symptomatic heart failure and EF ≤ 0.35, enalapril reduced all-cause mortality compared with placebo.35.2% vs 39.7%Read →
Device therapy & sudden death3
- 2009MADIT-CRTCardiology · Arrhythmia · CRTIn 1,820 patients with mild heart failure (NYHA I–II) and a wide QRS, adding resynchronisation to a defibrillator reduced death or heart-failure events compared with a defibrillator alone.HR 0.66Read →
- 2005SCD-HeFT CoreCardiology · Arrhythmia · ICDIn 2,521 patients with heart failure (NYHA II–III, EF ≤ 35 %), an implantable defibrillator reduced all-cause mortality compared with placebo or amiodarone.Read →
- 2002MADIT-II CoreCardiology · Arrhythmia · ICDIn 1,232 patients with prior MI and an ejection fraction ≤ 30 %, a prophylactic implantable defibrillator reduced all-cause mortality compared with conventional therapy.HR 0.69Read →
Structural comorbidity1
- 2023TRILUMINATECardiology · Structural · TricuspidIn 350 patients with severe symptomatic tricuspid regurgitation, transcatheter tricuspid repair improved quality of life compared with medical therapy.WR 1.48Read →
Cited landmark trials not yet in the register8
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2020LoDoCo2
Low-dose colchicine cut cardiovascular events in chronic coronary disease.
- 2019COLCOT
Colchicine after myocardial infarction.
- 2018CorMicA
Stratified therapy for angina with non-obstructive coronary arteries (ANOCA/INOCA).
- 2019THEMIS
Ticagrelor plus aspirin in diabetes with stable coronary disease.
- 2015PEGASUS-TIMI 54
Extended dual antiplatelet therapy with ticagrelor after MI.
- 2009BARI 2D
Revascularisation vs. medical therapy in diabetes.
- 2020ORION-10/-11
Inclisiran (siRNA) for LDL-cholesterol lowering.
- 2015PROMISE
Anatomical vs. functional first-line testing in suspected coronary disease.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.